Counseling Patients About Allergic Rhinitis

Swanson, Keith A.

doi:10.1016/s1086-5802(16)30061-4

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also may experience seasonal exacerbations of symptoms. 9,14 Although avoidance of the allergen is the best measure, many patients require pharmacotherapy for symptom relief.…”

Section: Allergic Rhinitis Mechanism Of Action Of Allergic Response Tmentioning

confidence: 99%

“…Agents such as systemic and topical antihistamines and decongestants, mast cell stabilizers, immunotherapy, and intranasal corticosteroids are all beneficial in treating certain symptoms. 8,14,18 Monoclonal antibodies are being studied as therapy for patients who do not adequately respond to other treatment options. 19 Systemic and topical antihistamines generally are considered first-line therapy for acute, occasional, or intermittent symptoms of seasonal and perennial allergic rhinitis.…”

Section: Treatment Of Allergic Rhinitismentioning

confidence: 99%

“…It is relatively safe for most patients, with side effects usually limited to local irritation of nasal mucosa. 14,25 Immunotherapy is a slow, gradual process of subcutaneously injecting the offending antigen in increasing dosages in hope of building immunity to the antigen. It generally is reserved for patients who have severe symptoms that disrupt activities of daily living, whose reactions are caused by only a few identifiable allergens, and who do not respond to other therapies.…”

Section: Mast Cellmentioning

confidence: 99%

“…Immunotherapy is expensive and may be life threatening if an anaphylactic reaction occurs. 14,26,27 Awaiting approval of the Food and Drug Administration is the anti-IgE monoclonal antibody olizumab, to be indicated for subcutaneous therapy of seasonal allergic rhinitis in adults and children. Olizumab is a recombinant humanized monoclonal antibody directed against circulating IgE.…”

Section: Mast Cellmentioning

confidence: 99%

See 3 more Smart Citations

Intranasal Corticosteroids for Allergic Rhinitis

2002

View full text Add to dashboard Cite

Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis. Several intranasal corticosteroids are available: beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, mometasone furoate, and triamcinolone acetonide. All are efficacious in treating seasonal allergic rhinitis and as prophylaxis for perennial allergic rhinitis. In general, they relieve nasal congestion and itching, rhinorrhea, and sneezing that occur in the early and late phases of allergic response, with studies showing almost complete prevention of late-phase symptoms. The rationale for topical intranasal corticosteroids in the treatment of allergic rhinitis is that adequate drug concentrations can be achieved at receptor sites in the nasal mucosa. This leads to symptom control and reduces the risk of systemic adverse effects. Adverse reactions usually are limited to the nasal mucosa, such as dryness, burning and stinging, and sneezing, together with headache and epistaxis in 5-10% of patients regardless of formulation or compound. Differences among agents are limited to potency, patient preference, dosing regimens, and delivery, device and vehicle.

show abstract

“…They also may experience seasonal exacerbations of symptoms. 9,14 Although avoidance of the allergen is the best measure, many patients require pharmacotherapy for symptom relief.…”

Section: Allergic Rhinitis Mechanism Of Action Of Allergic Response Tmentioning

confidence: 99%